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Despite continuous progress in our understanding of the pathogenesis of congestive heart failure (CHF) and its management,
mortality remains high. Therefore, development of reliable experimental models of CHF and cardiac hypertrophy is essential to
better understand disease progression and allow new therapy developement. The aortocaval ﬁstula (ACF) model, ﬁrst described
in dogs almost a century ago, has been adopted in rodents by several groups including ours. Although considered to be a model of
high-outputheartfailure,itslong-termrenalandcardiacmanifestationsaresimilartothoseseeninpatientswithlow-outputCHF.
These include Na+-retention, cardiac hypertrophy and increased activity of both vasoconstrictor/antinatriureticneurohormonal
systems and compensatory vasodilating/natriuretic systems. Previous data from our group and others suggest that progression of
cardiorenalpathophysiologyinthismodelislargelydeterminedbybalancebetweenopposinghormonalforces,asreﬂectedinstates
of CHF decompensation that are characterized by overactivation of vasoconstrictive/Na+-retaining systems. Thus, ACF serves as
a simple, cheap, and reproducible platform to investigate the pathogenesis of CHF and to examine eﬃcacy of new therapeutic
approaches. Hereby, we will focus on the neurohormonal, renal, and cardiac manifestations of the ACF model in rats, with special
emphasis on our own experience.
1.Introduction
Congestive Heart failure (CHF) is a clinical syndrome char-
acterized by cardiac dysfunction and myocardial structural
abnormality (e.g., hypertrophy and dilated cardiomyopathy)
resulting in inability of the heart to eject suﬃcient blood to
the metabolizing tissues. CHF is a leading cause of morbidity
and mortality, posing a major health and economic burden
intheWesternworld[1].Nearly5millionAmericansand6.5
million Europeans suﬀer from heart failure, which accounts
for 20% of all hospitalizations among patients over the age
of 65, and its related complications result in one million
admissions with an annual mortality rate of 8%–10% [2].
Moreover, CHF has enormous economic impact because of
the high costs of the treatment, frequent hospitalizations,
and poor quality of life. Therefore, understanding the
basic mechanisms leading to the development of CHF and
its complications, as well as the discovery of innovative
adequate treatment for CHF are crucial in order to improve
the outcome of this devastating disease. The ideal model
should be able to reproduce each of the aspects of the
progression of clinical CHF. However, none of the models
available is able to entirely reproduce CHF. While some
models reproduce neuroendocrine changes, others better
reproduce the remodeling that occurs during chronic heart
failure. Nevertheless, the progress that has been made so far
and the expected future achievements in this ﬁeld would
not have been possible without the continuous development
of experimental models of heart failure and hypertrophy
in small and large animals, where each one has its unique
advantages and limitations. Among these models, one can
mention coronary ligation, aortic banding, salt-sensitive
and spontaneous hypertension, toxic cardiomyopathy, rapid
pacing, and aortocaval ﬁstula (ACF) (for more details see
[3]). The latter was induced for the ﬁrst time in dogs in
1923, and adopted to rats in 1973 by Stumpe et al. [4, 5].2 Journal of Biomedicine and Biotechnology
The transition from large animals to rodents is of special
value since powerful genomic tools such as transgenic and
knockout technologies are now available for the rat in
addition to mice.
2. The Experimental Model of Aortocaval
Fistula:Methodological Aspects
Over the last 2 decades our group has been studying the
pathophysiology of heart failure using rats with ACF as
an experimental model of volume-overload CHF [6–13].
Heart failure is induced in this model by surgical creation
of an arteriovenous (AV) ﬁstula between the abdominal
aorta and inferior vena cava, distal to the origin of the
renal arteries, as described by Stumpe et al. [4]. In short,
under binocular magniﬁcation the common wall between
the inferior vena cava and the abdominal aorta is grasped
through a longitudinal incision made in the inferior vena
cava, and a ﬁstula is created between the 2 vessels (side
to side, 1.0–1.2mm in length). The opening in the vena
cava is then closed by a continuous suture (see Figure 1).
A similar procedure was adopted to produce severe cardiac
hypertrophyinthemouse[14].Otherinvestigatorshaveused
a simpliﬁed and quicker technique by insertion of a 18 gauge
needle through the abdominal aorta and creating a ﬁstula in
the common wall of the vessels, followed by closure of the
puncture in the aorta by cyanoacrylate glue [15, 16].
A unique property of our rats with ACF, not reported in
other experimental models of CHF, is the ability to divide
these animals into 2 subgroups based on the pattern of their
daily sodium excretion after creating the ﬁstula [7]. While
both subgroups show avid renal retention of sodium and
water in the early phase after surgery, the majority of ACF
rats (∼80%) can increase their urinary sodium excretion to
baseline levels and return to balance after 7–10 days. The
other subgroup continues to retain salt and water and dies
from symptoms of pulmonary edema and ascites formation,
similar to patients with severe clinical CHF. We termed
these subgroups as “compensated” and “decompensated”
CHF rats,respectively,whichallowed us to characterizethese
subgroups and study the factors that may contribute to
deterioration from compensated to a decompensated state
(Figure 2 and Table 1)[ 7, 10].
It should be emphasized that the AV ﬁstula model has
been used also in other species, primarily dogs, to study
the pathophysiology of CHF [18–24]. Also, the circulatory
and renal consequences in patients with posttraumatic AV
ﬁstula were reported in classic studies in the past and served
in many respects as a drive for the investigations in the
animal models [25–27]. The current review summarizes the
neurohormonal,renalandcardiaccharacteristicsofratswith
ACF, with special focus on our own studies.
3. Neurohormonal Alterations
3.1.Vasoconstrictor/AntinatriureticSystems. Creation ofACF
results in an immediate and sustained decrease in mean
arterial pressure together with a substantial increase in
venous blood ﬂow to the right heart. These hemodynamic
changes result in compensatory activation of several neuro-
hormonalsystemsaswellasinadaptivestructuralalterations
in myocardium and vascular system, as shown previously by
other investigators [19, 28, 29]. Among the neurohumoral
systems that are activated in response to ACF creation one
can ﬁnd the classical vasoconstrictor/antinatriuretic systems
including the renin-angiotensin-aldosterone axis (RAAS),
the sympathetic nervous system (SNS), the antidiuretic
hormone (ADH) and the endothelin-1 (ET-1), acting via
the ETA receptor. Activation of the classic vasoconstrictor
systems is thought to be mediated in part by the sustained
decrease in MAP that occurs following the placement of the
ﬁstula, sensed by the baroreceptors in the arterial circulation.
Both the increased activity of the SNS with high circulating
levels of catecholamines, as well as the increase in the
nonosmotic ADH release may be mediated by a similar
mechanism. In addition, renal hypoperfusion may serve as
a potent stimulus for the activation of the RAAS.
The RAAS plays a fundamental role in the pathogenesis
of the cardiovascular and renal manifestations in exper-
imental models of CHF, in particular in rat and canine
models of ACF [7, 30–33]. Although initially activated to
support systemic BP by direct systemic vasoconstriction,
by facilitating the central and peripheral eﬀects of the
sympathetic nervous system and by promoting renal sodium
retention, many of the biological activities of the system turn
to be “maladaptive” during the progression of the disease,
and contribute signiﬁcantly to the deterioration, both in
clinical and in experimental CHF models [34]. In particular,
recent studies implicated both angiotensin II (ang II) and
aldosterone as potential mediators of the deterioration in
cardiac and renal function in severe CHF [9, 35].
The RAAS is activated in the early phases after creation
of the AV ﬁstula and plays a major role in the induction
of cardiac hypertrophy and changes in renal function in
this model [12, 31, 32, 36]. In particular, we have shown
that the main diﬀerence between the “compensated” and
“decompensated” subgroups of rats with ACF relates to the
degree of activation of the RAAS in these subgroups, as
evaluated by their plasma renin activity (PRA) [7]. Increased
activity of the RAAS is thought to act by “blocking” the
natriuretic/vasodilatory eﬀect of ANP in the kidney, thereby
leading to avid renal sodium and water retention and edema
formation [13, 33]. In addition, increased activity of the
RAAS may contribute to the impairment of endothelial-
dependent renal vasodilatation and the development of
“endothelial dysfunction” in rats with ACF [11]. In view of
the central role of the RAAS in the induction of CHF in
animals with ACF it is not surprising that pharmacological
blockade of this neurohumoral axis either by ACE inhibitors
or angiotensin receptor blockers (ARBs) provides beneﬁcial
eﬀects in this experimental model of CHF [7, 32, 33, 37, 38].
The SNS is another vasoconstrictor/antinatriuretic sys-
tem that is activated in early in the course of CHF [39].
While the role of the SNS in mediating systemic and renal
vasoconstriction and sodium retention is well established
in other experimental models of CHF, the contribution of
increased sympathetic activity in animals with ACF has notJournal of Biomedicine and Biotechnology 3
Table 1: Neurohumoral, hemodynamic and renal characteristics of sham operated rats and rats with compensated and decompensated CHF
(see [7, 8, 10, 12, 17]).
Parameter Sham CHF-compensated CHF-decompensated
Neurohumoral
PRA (ngAng/ml/min) 14.0 ± 3.0 31.2 ± 20.2 47.0 ± 14.0
Aldosterone (pg/ml) 243.9 ± 72.1 399.1 ± 57.9a 1266.4 ± 252.4a,b
AVP (pg/ml) 14.2 ± 3.6 36.1 ± 13.8a 37.7 ± 9.6a
Epinephrine (pg/ml) 667 ± 175.9 449.0 ± 339.0 2049.8 ± 496.9a,b
Norepinephrine (pg/ml) 184.2 ± 40.5 481.0 ± 20.0a 1112.6 ± 293.2a,b
ANP (pg/ml) 94 ± 12 382 ± 115a 389 ± 135a
Hemodynamic
CVP (mmHg) 4.5 ± 1.6 16.4 ± 3.9a
MAP (mmHg) 151 ± 4 125 ± 5a 103 ± 5a,b
CO (ml/min) 72.6 ± 5.9 114.9 ± 15.5a
Renal
GFR (ml/min) 1.96 ± 0.16 1.57 ± 0.21a 0.89 ± 0.12a,b
RBF (ml/min) 6.01 ± 0.29 2.81 ± 0.14a 2.17 ± 0.12a
UNaV (mEq/min) 1.69 ± 0.49 0.45 ± 0.08a 0.16 ± 0.11a,b
PRA: Plasma renin activity, AVP: Arginine vasopressin, ANP: Atrial natriuretic peptide, CVP: Central venous pressure, MAP: Mean arterial pressure,C O :
Cardiac output, GFR: Glomerular ﬁltration rate, RBF: Renal Blood ﬂow, UNaV: Urinary sodium excretion.
aP<. 05 versus sham operated rats, bP<. 05 versus compensated CHF. Values are means + SEM.
Inferior
vena cava
Abdominal aorta
AV ﬁstula
(1.2mm O.D.)
Figure 1: A schematic description of the creation of aortocaval
ﬁstula (ACF) in rats, an experimental model of volume-overload
CHF.
been studied thoroughly. Earlier studies suggest that there
is an attenuated response of aortic baroreceptor discharge
in dogs with chronic volume overload due to ACF, and this
abnormality may partially be responsible for the abnormal
baroreﬂex in heart failure [19, 40]. In other studies in
dogs with ACF Villarreal et al. [24, 41] demonstrated that
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Figure 2: Daily urinary sodium excretion (UNaV) in rats with
arteriovenous (AV) ﬁstula and in sham controls. Notice 2 distinct
patterns of sodium excretion in rats with AV ﬁstula, compensated
and decompensated that are statistically diﬀerent (P<. 05)
compared with sham controls. ∗P<. 05 versus sham-operated rats.
renal denervation improved the natriuretic response to atrial
natriuretic peptide and postprandial sodium excretion, sug-
gesting that increased renal sympathetic activity contributes
to salt retention in this canine model of CHF.
Antidiuretic Hormone (ADH) is synthesized in the brain
and secreted from the posterior pituitary gland into the
circulation in response to an increase in plasma osmolality
(via osmoreceptor stimulation) or a decrease in eﬀective
circulating volume and blood pressure (via baroreceptors
stimulation) [42]. ADH exerts its biological actions through
G-proteincoupledreceptors.Twoofthesereceptors,V1A and
V2, are abundantly expressed in the cardiovascular system
and the kidney and mediate the two main biological actions
of the hormone, namely, vasoconstriction and increased4 Journal of Biomedicine and Biotechnology
water reabsorption by the kidney [43]. ADH plasma levels
are elevated in experimental CHF, including rats with ACF
[44]. Similarly, numerous studies have demonstrated that
plasma levels of ADH are elevated in patients with CHF
mostly in advanced CHF with hyponatremia, and also
in asymptomatic patients with left ventricular dysfunction
[45,46].Themechanismsunderlyingtheenhancedsecretion
of ADH in CHF are related to nonosmotic factors such as
attenuated compliance of the left atrium, hypotension, and
activation of the RAAS [47, 48]. Since the main eﬀect of
ADH in CHF is the production of hyponatremia, it will be
discussed in the section of renal manifestation [47, 49].
The endothelin system consists of 3 vasoactive peptides,
namely,endothelin-1(ET-1),endothelin2(ET-2),andendo-
thelin 3 (ET-3). These peptides are synthesized and released
mainly by endothelial cells and act in a paracrine/autocrine
mode of action [50, 51]. Endothelin-1, the main represen-
tative of the ET family, is the most potent vasoconstrictor
knownatpresent.TheETsbindtotwodistinctreceptorsdes-
i g n a t e dE T Aa n dE T B .B o t hr e c e p t o r sa r ee x p r e s s e di nav a r i -
ety of tissues, including blood vessels, kidney, myocardium,
lung, and brain [50–52]. The vasoconstrictor response to ET
is induced by a ETA receptor mediated increase in cytosolic
Ca2+.Theendothelium-dependentrelaxationismediatedby
the ETB receptors via NO and PGs coupled mechanism. The
kidney is both a source of ET production (mainly the inner
medulla) and an important target organ of the peptide.
The pathophysiological role of ET-1 in CHF is supported
by two major lines of evidence: (1) Several studies have dem-
onstrated that the ET system is activated in CHF [53–55].
(2) Some clinical and experimental studies have shown
that ET-1 receptor antagonists modify this pathophysiologic
process. The ﬁrst line of evidence is based on the demon-
stration that plasma ET-1 levels and the concentrations
of its precursor, Big ET-1, are elevated both in clinical
CHF and experimental models of CHF, and correlate with
hemodynamic severity and symptoms [56, 57]. In rats with
ACF, there was a prompt three-to-fourfold increase in ET-
1 mRNA in atria and a progressive ﬁve-to-sevenfold rise
in ventricles during cardiac hypertrophy [58]. Cavero et al.
[59] reported that plasma immunoreactive ET-1 levels are
elevated2-to3-foldabov enormalindogswithCHFinduced
by rapid ventricular pacing. Elevated circulating ET-1 levels
have also been reported in patients with CHF [56].
3.2. Vasodilatory/Natriuretic Systems. Concomitantly with
the stimulation of the vasoconstrictor neurohumoral sys-
tems,compensatoryvasodilatory/natriuretic systemsarealso
activated in rats with ACF, serving to counterbalance the
actions of the opposing vasoconstrictor systems. Among
thesevasodilatory/natriureticagents,thoseparticularlystud-
ied in animals with AV ﬁstula are the natriuretic pep-
tides, primarily atrial natriuretic peptide (ANP), the nitric
oxide (NO) system, and the vasodilatory prostaglanding E2
(PGE2).Inmanyrespects,thecardiovascularandrenalstatus
in rats with ACF is determined by the balance between these
opposing neurohumoral systems, as will be outlined in the
following sections.
Atrial natriuretic peptide (ANP) and B-type natriuretic
peptide (BNP) are circulating hormones of cardiac ori-
gin which play important roles in the compensation of
congestive heart failure with their vasodilating, natriuretic,
antiproliferative, and neurohumoral-modulating properties
[60,61].ThenatriureticpeptidesandinparticularANPhave
been studied extensively in the ACF model of CHF [6, 7,
23, 33, 62–64]. This experimental model is characterized by
a marked increase in right atrial pressure as a consequence
of the diversion of a large proportion of the arterial blood
ﬂow to the venous circulation. Given that distention of atria
is the most potent physiological stimulus for ANP release
into the circulation, it is reasonable to assume that plasma
levelsofANParemarkedlyelevatedinthismodel.Indeed,we
demonstrated that plasma levels of ANP were approximately
20 times higher compared with sham-operated controls.
Plasma ANP increased already 24hrs after creation of the
ﬁstula and remained elevated for the entire ﬁrst week of
observation, to the same extent in both the “compensated”
and the “decompensated” subgroups of rats with ACF [7].
In similarity with patients with heart failure, signiﬁcant
elevations in plasma ANP levels were reported by other
investigators also in the canine model of ACF as well as
in other experimental models of CHF [24, 33, 65–67]. The
common ﬁnding of high circulating ANP levels in CHF
appears to be at odds with the tendency to salt and water
retention by kidney, a characteristic ﬁnding in patients and
experimental models of CHF that might suggest that the
natriuretic/diuretic eﬀects of the peptide are attenuated in
CHF.Themechanismsproposedtoexplainthephenomenon
of “ANP resistance” in CHF include hemodynamic changes
leading to a decrease in renal perfusion, activation of
vasoconstrictor/antinatriuretic neurohumoral systems such
as the RAAS and SNS, downregulation of ANP receptors,
increased degradation of ANP or its 2nd messenger cGMP,
and release of less active forms of ANP in CHF [13]. A con-
sistent ﬁnding in our studies is the observation that removal
of the inﬂuence of the RAAS, by ACE inhibitors or ARBs
improves the natriuretic response to ANP administration in
rats with ACF [7, 8, 37]. Similar observations were reported
by Villarreal and coworkers in the canine model of ACF
[23].Otherneurohumoralvasoconstrictors,suchastheSNS,
may participate as well [41]. The cellular mechanisms by
which the RAAS attenuates the natriuretic action of ANP
are complex and incompletely understood. Based on our
studies in rats with ACF, it appears that the interference with
ANP signaling in CHF could involve changes at receptor
level, the 2nd messenger of the peptide, and beyond the 2nd
messenger of ANP [13, 62, 68, 69]. Smith and Lincoln [70]
were the ﬁrst to demonstrate in cultured vascular smooth
muscle cells and mesangial cells that angiotensin II, and
perhaps other vasoconstrictor Ca2+ mobilizing agents, may
increase the degradation of cGMP, the 2nd messenger of
ANP, by activation of Ca2+-dependent phosphodiesterase.
This potential mechanism is of interest since we have
demonstratedthaturinarycGMPexcretionisreducedinrats
with ACF; however, cGMP generation in isolated glomeruli
from ACF rats as tested in vitro in response to ANP remains
intact [69]. Moreover, administration of the ARB losartanJournal of Biomedicine and Biotechnology 5
can restore the ANP-mediated cGMP excretion in ACF rats
with decompensated CHF, suggesting that interference in
ANP signaling in this model occurs at a step beyond cGMP
generation [37, 69].
The concept that urinary salt and water excretion is
determined by the balance between ANP and the RAAS is
important not only because it can elucidate the mechanisms
of “ANP resistance” in CHF but because of its potential
therapeutic implications. Indeed, potentiating the biologic
eﬀects of ANP in CHF may be achieved either by removing
the inﬂuence of the RAAS or by enhancing the eﬀects
of ANP or its 2nd messenger cGMP. The latter approach
utilizes pharmacologic agents that inhibit the enzymatic
degradation of ANP by neutral endopeptidase (NEP), an
endothelial cell surface metalloproteinase that is involved
in the degradation of several regulatory peptides, including
the natriuretic peptides. Combined NEP/ACE inhibitors, the
so-called vasopeptidase inhibitors, reduce vasoconstriction
and enhance vasodilatation and natriuresis apparently by
blocking angiotensin II generation and the degradation of
the natriuretic peptides [71]. Indeed, we have demonstrated
that Omapatrilat, a drug belonging to the group of vasopep-
tidase inhibitors, improves both sodium balance and cardiac
remodeling in rats with ACF and might be advantageous
to ACE inhibitors for the treatment of decompensated CHF
[72]. Finally, an early study by Wilkins and coworkers
[73] demonstrated that administration of a selective cGMP
phosphodiesterase inhibitor, M&B-22948 increased urinary
sodium excretion and restored the natriuretic response
to exogenous and endogenous ANP in rats with ACF,
supporting the notion that enhanced degradation of cGMP
can limit the natriuresis induced by ANP in this model of
CHF. The more recent development of highly selective and
potent inhibitors of phosphodiesterase-5 (PDE-5) provides
an opportunity to test the contribution of this pathway to
the mechanism of blunted responsiveness to the natriuretic
peptides in CHF [74]. Indeed, such a mechanism was found
to be of importance in dogs with rapid pacing-induced
chronic CHF [75]. Unfortunately, the eﬃcacy of these agents
was not tested in the rat model of ACF.
Two other important vasodilatory/natriuretic systems,
namely, the nitric oxide (NO) and the vasodilatory prostagl-
andins, have been studied in rats with ACF, mainly in the
context of regulation of renal blood ﬂow (RBF) in exper-
imental CHF, and therefore will be alluded to in the section
on renal manifestations of rats with ACF.
4. Renal Manifestations
The kidney plays a key role in the pathogenesis of CHF
[36,76].Themainchangesobservedinpatientsandinexper-
imental models of CHF include alterations in the regulation
of RBF and sodium and water excretion that can contribute
to the development of positive sodium balance, edema
formation, and deterioration into a state of decompensated
heart failure. Over the years, our group and others have
studied the renal manifestations in this rat model of CHF.
The main observations are summarized in the following
section.
A decrease in RBF is one of the earliest and most
consistent ﬁnding in patients with CHF [76]. Traditionally,
this decrease in renal perfusion has been attributed to a
combination of several pathogenetic mechanisms: a reduc-
tion in the pumping capacity of the failing myocardium
combined with compensatory activation of neurohormonal
vasoconstrictor systems such as the RAAS, SNS and ADH
[36, 76]. We have shown repeatedly that RBF, measured
directly by ultrasonic ﬂowmetry, is reduced by more than
50% in rats with ACF [17] (see Table 1). Concomitant with
the decrease in RBF there is also a decrease in glomerular
ﬁltration rate (GFR) that is more pronounced in CHF rats
with decompensated CHF (Table 1). Our studies clearly
underscore the importance of the RAAS in mediating the
alterations in renal hemodynamics in this experimental
model of CHF [11, 12]. As pointed out earlier, activation of
the RAAS is one of the earliest compensatory neurohumoral
responses to the decrease in the pumping capacity of the
failing myocardium in CHF [30, 36]. In particular, angII
seems to play an important role in mediating the changes
in renal hemodynamics in CHF, in view of the unique
sensitivity of the kidney to the vasoconstrictor action of
this peptide on the aﬀerent and eﬀerent arterioles and on
mesangial cells [77]. The importance of angII in mediating
the decrease in RBF was shown in our previous study in
which acute infusion of the ARB eprosartan resulted in a
prompt and sustained increase in RBF in rats with ACF
[12]. In addition to the RAAS other vasoconstrictors, such
as increased SNS activity, may participate in mediating renal
hypoperfusion although the role of the latter system was not
studied by us in this model.
ET-1 is another potent vasoconstrictor implicated in
the mediation of renal hypoperfusion in CHF. Artiﬁcial
increase of plasma ET-1 levels in experimental animals to
concentrations found in patients with CHF [78] is associated
with signiﬁcant reduction in RBF and increased vascular
resistance. Bearing in mind that CHF is characterized by
reduced RBF associated with increased vascular resistance
along elevated levels of ET-1, it is appealing that a cause and
eﬀect relationship between these hemodynamic abnormali-
ties and ET-1 exists in this disease state. The role of the ET-1
system in mediating the alterations in renal hemodynamics
in rats with ACF has been studied extensively by our group
[79]. First, we showed that the intrarenal ET system is
activated in ACF rats by demonstrating that the endothelin
converting enzyme (ECE) is upregulated in the kidneys
of rats with ACF [79–82]. Second, by using selective ETA
and ETB receptor antagonists combined with RT-PCR and
Western blot evaluation of the renal ETA and ETB receptor
expression and immunoreactive levels, we showed that CHF
is associated with altered regulation of intrarenal blood ﬂow,
which reﬂects alterations in expression and activity of the
ET and NO systems. We further suggested that exaggerated
NO activity in the medulla contributes to preservation of
medullary blood ﬂow in the face of cortical vasoconstriction
in rats with ACF [80]. Third, we demonstrated that the
ETA and ETB receptors are diﬀerentially regulated in the
kidneys of ACF rats with compensated and decompensated
CHF [81]. While compensated CHF was associated with6 Journal of Biomedicine and Biotechnology
upregulation of ETB in the collecting duct and vasa recta,
decompensated CHF was accompanied with enhanced ETB
abundance in the vasa recta and remarkable downregulation
of this receptor subtype in the collecting duct. This suggested
that upregulation of ETA may lead to a decrease in cortical
blood ﬂow, while upregulation of ETB in the vasa recta
probably contributed to the preservation of medullary blood
ﬂow. Furthermore, downregulation of ETB in the collecting
duct,onlyinratswithdecompensatedCHF,couldcontribute
to sodium retention in that subgroup [81]. Finally, we
studied the eﬀects of chronic blockade of the ETA and
ETB receptor by selective antagonist on renal hemodynamics
and excretory functions in rats with ACF [82]. Chronic
treatment with an ETA receptor blocker totally abolished the
systemic and renal vasoconstriction caused by injected ET-1
in rats with ACF whereas a selective ETB receptor antagonist
potentiated these eﬀects. Chronic treatment of animals with
congestive heart failure with ETA blocker did not inﬂuence
daily sodium excretion whereas treatment with ETB antago-
nist signiﬁcantly improved daily sodium excretion [82]. For
the sake of clarity it should be mentioned that the use ET
antagonists such as Darusentan did not improve the clinical
manifestations an outcome in patients with CHF treated by
conventional therapy [83]. This discrepancy between clinical
and experimental CHF could be attributed to diﬀerences in
the severity of and etiology of CHF, as well as the doses and
time of drugs administration.
ThecontrolofRBFinexperimentalCHFisassociatednot
only with alterations in the vasoconstrictor arm of the regu-
latory system. Indeed, one of the important breakthroughs
in the last century was the discovery of role of endothelial
cells in the regulation of blood ﬂow and the recognition of
the importance of locally released vasodilatory substances,
in particular NO, in the regulation of RBF and systemic
hemodynamics [84]. In this regard, we demonstrated in rats
with ACF an impaired endothelial-dependent vasorelaxation
in response to acetylcholine administration, suggesting that
the decrease in RBF is not related only to increased activity
of vasoconstrictor systems but also reﬂects the failure of the
endothelial-dependent NO action [11]. Moreover, similar
to the mechanism of the impaired natriuretic response to
ANP, increased activity of the RAAS played a key role in
mediating this phenomenon since treatment with the ARB
A-81988 resulted in almost a complete restoration of renal
endothelial-dependent vasodilatation in this model [11]. We
have also shown that the NO system plays a crucial role
in the maintenance of intact blood perfusion to the renal
medulla in rats with ACF, despite a signiﬁcant decrease
in total RBF [80]. This is achieved by upregulation of
the endothelial-derived NO synthase in the renal medulla,
suggesting that exaggerated NO activity in the medulla
contributes to preservation of medullary blood ﬂow in the
face of cortical vasoconstriction in CHF.
Another important system that participates in the regu-
lation of RBF in animals with ACF is the renal prostaglandin
system. Early studies demonstrated that prostaglandins are
involved in the maintenance of RBF and GFR in the
canine model of ACF, and that indomethacin administra-
tion produced striking reductions in renal hemodynamic
function [21]. More recent studies by our group disclosed
the importance of the system in the maintenance of renal
medullary blood ﬂow in rats with ACF [85]. We evaluated
the relative expression and immunoreactive levels of the
cyclooxygenases 1 and 2 (COX-1 and COX-2), the enzymes
involved in the synthesis of the PGs from arachidonic acid,
in the renal cortex and medulla of rats with ACF, and
examined the eﬀects of selective and nonselective inhibitors
of these COX isoforms on cortical and medullary blood ﬂow.
We found that both COX-1 and COX-2 are predominantly
expressedintherenalmedullaandthatratswithACFdisplay
selectiveoverexpressionofCOX-2.Thelattermayrepresenta
mechanism aimed at defending medullary blood ﬂow in the
face of a decrease in total and cortical blood ﬂow during the
development of CHF [85].
In addition to changes in renal hemodynamics, rats with
ACF are characterized also by alterations in renal salt and
water retention. The mechanisms leading to salt retention
and the interactions between the RAAS and other vasocon-
strictors with ANP in determining the ﬁnal balance of salt
excretion have been described in early parts of this review.
There is, however, abundant evidence that both clinical and
experimental CHF are associated with alterations in the
ADH-renal water transport axis, independent of regulation
of renal sodium transport. The most recognized renal eﬀect
of ADH in CHF is the development of hyponatremia which
usually occurs in advanced stages of the disease and may
occur at concentrations much lower than those required for
vasoconstriction[48].Thisphenomenonhasbeenattributed
to water retention by the kidney due to sustained release
of ADH, irrespective of plasma osmolality. Mulinari and
associates [86] have demonstrated that administration of an
ADH antagonist with dual V1/V2 antagonism to rats with
ischemic CHF induced by left coronary ligation resulted in
a rise in cardiac output, a decline in PVR, and an increase
in urine output of 4- to 10-fold over baseline, conﬁrming
the role of ADH in the water retention and the increased
vascular resistance of CHF. Recent reports have provided
further insights into the mechanisms of ADH-mediated
waterretentioninexperimentalCHF.Thesestudiesinanimal
models of CHF have also demonstrated an increased renal
expression of AQP2 in these animals, suggesting that this
may also contribute to the enhanced water reabsorption in
the CD [87]. It is therefore not surprising that initial studies
have shown that administration of V2 vasopressin receptor
antagonists of peptidic and nonpeptidic nature to rats
with inferior vena cava constriction [88], dogs with CHF-
induced by rapid pacing [89], and rats with CHF-induced
by coronary ligation [48]h a v er e s u l t e di nc o r r e c t i o no ft h e
impaired urinary dilution in response to acute water load.
The mechanism underlying these expected ﬁndings rely on
the fact AQP2 are expressed in the collecting duct and medi-
ate the antidiuretic action of ADH [88, 90] Furthermore, the
expression of AQP2 and its immunoreactive levels has been
reported to be elevated in the kidney of rats with experi-
mental CHF induced by coronary artery ligation [91, 92].
Oral treatment of these rats with V2 antagonist (OPC31260)
induced signiﬁcant diuresis, a decrease in urinary osmolarity
and increased plasma osmolarity, which were associatedJournal of Biomedicine and Biotechnology 7
with downregulation of renal AQP-2 [91]. These ﬁndings
indicate a major role for ADH in the upregulation of AQP2
water channels and subsequently enhanced water retention
in experimental CHF. Similarly, we have demonstrated that
acute administration of SR 121463B (V2 antagonist), but not
SR 49059 (V1 antagonist), to rats with ACF caused a fourfold
increase in urinary ﬂow rate [44]. The diuretic eﬀects of SR
121463B were associated with a signiﬁcant decline in urinary
osmolality and insigniﬁcant change of Na+ excretion. In line
with its acute eﬀects, chronic administration (4 weeks) of SR
121463B to CHF rats increased daily urinary volume up to
5-fold throughout the treatment period. In agreement with
the studies in experimental animals, several recent clinical
studies have demonstrated that chronic treatment with
selective V2 and dual V1a/V2 antagonists may be beneﬁcial
in the correction of hyponatremia in CHF [49, 93, 94]. For
instance, administration of the oral selective V2 receptor
antagonist VPA-985 to patients with CHF for seven days
at incremental doses induced signiﬁcant diuretic response
accompanied by increase in plasma Na+ concentration and
decreased urine osmolarity [95]. Similarly, when YM087,
an orally V1/V2 antagonist was given to orally to patients
with CHF it increased plasma Na+ reduced osmolarity of
the urine and increased urine output [93, 96]. Collectively,
these data suggest that ADH is involved in the pathogenesis
of water retention and hyponatremia that characterize CHF
including rats with decompensated CHF due to ACF, and
that vasopressin receptor antagonist results in remarkable
diuresis in both experimental and clinical CHF.
5. CardiacManifestation
Rats with ACF are characterized by cardiac hypertrophy
and dilatation, as well as myocardial remodeling [6–12]
Cardiac hypertrophy is also a major characteristic of many
cardiovascular disorders and is considered to be a major risk
factor of cardiovascular mortality and morbidity [97]. The
increased ventricular mass is a general adaptive response to
states of cardiac hyperfunction [10, 31, 37, 98–100], and is
observed in a wide range of physiological and pathologic
states, including pressure overload, volume overload, and
excessive exposure to neurohumoral and metabolic stimuli.
It should be emphasized that the biochemical and mor-
phological responses of myocytes depends on the speciﬁc
inciting stimulus. For example, thyroid hormone-induced
hypertrophy in myocytes diﬀers from that induced by α-a n d
β-adrenergic stimuli [101, 102]. Further, the characteristics
of the cardiac hypertrophic response diﬀer among various
forms of exercise, aortic stenosis [103], genetic hypertension,
or hypertension caused by renal artery stenosis [104].
Therefore, several animal models were developed to create
cardiovasculardiseases,CHF,andcardiachypertrophy-based
on the etiology of the corresponding clinical situations. The
dynamic nature of CHF is exempliﬁed by the observations
that at its ﬁrst stages, hypertrophy is an appropriate and
adaptive response to elevate pressure/volume overload; how-
ever, it often progresses to the decompensated stage and
CHF [98]. With the progression of the initial stimulus,
a transition occurs in which an irreversible decompensation
in cardiac function takes place, leading to heart failure,
as well as to an increased tendency to develop sodium
retention, edema, dyspnea, and arrhythmias [105, 106]. The
trigger for this transition from compensated hypertrophy to
decompensation is unknown. By macroscopic morphology,
decompensated hypertrophy and heart failure are usually
characterized by ventricular dilation [106].
ACF model has become the most frequently used
technique to induce volume overload hypertrophy followed
by heart failure in rats [107–109]. Several studies have
demonstrated that a surgically installed ﬁstula between the
aorta and the vena cava causes a drastic volume overload on
the heart, which results in marked left and right ventricular
hypertrophy few weeks after surgery [15, 110]. In fact,
studies from our laboratory have shown remarkable cardiac
hypertrophy/remodeling, in correlation with the severity of
the heart failure, even after one week from the creation of
ACF [10, 12, 31]. For instance, heart/body weight, an index
of cardiac hypertrophy, increased by 41% and 75% in rats
with compensated and decompensated CHF, respectively,
7 days after the placement of surgical ﬁstula between the
aorta and vena cava (Figure 3). Although various causes
of cardiac remodeling share several molecular, biochemical
and mechanical pathways, diﬀerent stimuli induce diverse
ventricularremodelingpatterns.Ingeneral,thehypertrophic
pattern in response to volume overload diﬀers from that in
pressure overload, both morphologically and biochemically
[110, 111]. For example, pressure overload-induced cardiac
hypertrophy occurs in many clinical settings that include
hypertension, mitral valve stenosis, and aortic valve stenosis.
When subjected to one of these negative stimuli, the
heart undergoes concentric remodeling due to increased
cardiomyocytes diameter in order to normalize wall stress
due to the increase in pressure exerted on the cardiac tissue
[112–114]( Figure 4). In contrast, volume overload results
in cardiomyocytes lengthening and eccentric hypertrophy
(Figure 4)[ 113, 114]. The latter condition is caused by
anemia, heart block, regurgitant mitral or aortic valves, atrial
or ventricular septal defects, or ACF [115]. Indeed, rats with
ACF develop eccentric hypertrophy, which results in left
ventricular (LV) dilatation and a concurrent elevation in
stroke volume in order to compensate for the excessive blood
volume delivered to, or remaining in the LV (Figure 4(b)).
Dilatation of the LV chamber occurs via elongation of
the surrounding myocytes, which results from sarcomeric
replication in series [115]. The diﬀerences between cardiac
remodeling in pressure and volume overload are largely
inﬂuenced by hemodynamic load, neurohumoral activation
and additional factors such as endothelin, cytokines, nitric
oxide(NO)productionandoxidativestress[116].Oneofthe
main vasoconstrictor neurohumoral systems, which play a
key role in the pathophysiology cardiac hypertrophy in CHF,
is the renin-angiotensin-aldosterone system (RAAS) [36,
117, 118]. Prolonged activation of the RAAS has direct dele-
terious actions on the myocardium, independent of its sys-
temic hemodynamic eﬀects [119]. Speciﬁcally, angiotensin II
(Ang II) has been shown to stimulate myocyte hypertrophy
and to enhance ﬁbrosis and apoptosis, leading ultimately to8 Journal of Biomedicine and Biotechnology
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Figure 3: Cardiac hypertrophy expressed as heart weight/body
weight ratio (HW/BW%) in rats with compensated and decompen-
sated CHF, one week after the placement of AV ﬁstula. ∗P<. 05
versus sham-operated rats; #P<. 05 versus compensated rats with
AV ﬁstula. Values are means ± SEM.
progressive remodeling and further deterioration in cardiac
performance [120]. The adverse contribution of aldosterone
to the functional and structural alterations of the failing
heart was elegantly demonstrated by Suzuki et al. [121].
These authors showed that eplerenone, a speciﬁc aldosterone
antagonist, prevented progressive LV systolic and diastolic
dysfunction in association with reducing interstitial ﬁbrosis,
cardiomyocyte hypertrophy and LV chamber sphericity in
dogs with CHF induced by intracoronary microemboliza-
tions.Similarly,Delyanietal.[122]reportedthateplerenone,
attenuated the development of ventricular remodeling and
reactive but not reparative ﬁbrosis after myocardial infarc-
tion in rats. In line with these adverse eﬀects of the RAAS on
cardiac hypertrophy and remodeling in low cardiac output
CHF models, we and others demonstrated that ACE, Ang
II and aldosterone inhibition by enalapril, eprosartan, or
spironolactone, respectively, reduced cardiac hypertrophy
andﬁbrosisandatthesametimecausedasigniﬁcantincrease
in urinary sodium excretion when administered chronically
in rats with ACF [7–9, 12, 32].
Additional system of special interest in the pathogenesis
o fc a r d i a ch y p e r t r o p h ya n dr e n a ld y s f u n c t i o ni nC H F
is the natriuretic peptides system. As mentioned above,
plasma levels of ANP are chronically elevated in several
pathological conditions, including CHF and are found to
be related to atrial pressure [123–125]. Actually, the highest
concentrationsofANPinthecirculationoccurinCHF[123–
125]. Moreover, plasma levels of ANP in CHF have been
found to correlate with the severity of cardiac failure, as well
as with the elevated atrial pressure and other parameters of
left ventricular dysfunction. In rats with experimental CHF
due to ACF, we reported high comparable levels of plasma
Pathological cardiac remodeling
Normal Eccentric
hypertrophy
Concentric
hypertrophy
(a)
RV LV
Baseline Week 4 after
surgery
Week 10 after
surgery
(b)
Figure 4: (a) A scheme showing pathological cardiac remodeling,
eccentric versus concentric hypertrophy. (b) MRI images of hearts
from sham controls and rats with aortocaval ﬁstula at diﬀerent
time points. Notice that rats with AV ﬁstula exhibited cardiac
hypertrophy dilation compared with sham controls.
ANP in both compensated and decompensated CHF [7]
(Table 1). Similar to ANP, plasma levels of BNP, which is
produced mainly by the ventricles in response to ventricular
stretch and pressure overload [126, 127], are elevated in
patients with CHF in proportion to the severity of the
myocardial systolic and diastolic dysfunction. Hoﬀman et al.
[6] demonstrated that rats ACF have high levels of BNP in
the plasma. Similarly, the enhanced plasma levels of BNP
coincides with overexpression of BNP in the myocardium of
rats with ACF [128], corresponding with the high volume
overload and cardiac hypertrophy characterizing this model
of CHF.
While cardiac hypertrophy and ventricular dilation
develop rapidly (within 1-2 weeks) in response to volume
overload in animals with ACF [9, 10, 12, 13], the evolvement
of heart failure in this model may take several weeks to few
months. In this regard, Brower et al. [129] examined the
eﬀect of the creation of ACF induced by 18-guage needle
that was inserted into the exposed abdominal aorta and
advancedthroughthemedialwallintothevenacavatocreate
a ﬁstula, on cardiac hypertrophy and ventricular dilation
1, 2, 3, 5, and 8 weeks post ACF placement. Progressive
hypertrophy and left and right ventricular hypertrophy in
association with decline in ventricular stiﬀness and contrac-
tilityoccurredthroughoutthefollowupperiod.Interestingly,
systolic function was preserved due to the compensatory
remodeling of the myocardium. Similarly, Huang et al. [130]
have shown that cardiac output is maintained at normal or
even enhanced levels during the early phase of ACF (i.e., <8
weeks). According to Brower et al. [129] reports, only 3%
of the rats with ACF progress toward overt CHF during the
8 weeks post the ﬁstula placement. However, the increaseJournal of Biomedicine and Biotechnology 9
in BW and lung weight seen in about 50% of rats with
ACF, suggests a consistent development of CHF. When rats
with ACF were monitored for longer periods, namely, 16–
21 weeks post ACF, the mortality rate was 80% due to CHF,
which occurred once the myocardial hypertrophic response
was exhausted [131, 132]. Collectively, these studies suggest
thatthedevelopmentofdecompensatedhypertrophyorCHF
occurs in low percentage at least 8 weeks after the creation
of ACF, but requires about 16 weeks to reach its maximal
incidence.
Keen evidence for the responsibility of the ACF for the
development of cardiac, renal, and neurohormonal pertur-
bations is derived from several studies where the eﬀect of
ACF closure on these parameters was studied. Surgical repair
of the ACF in the symptomatic patient resulted in resolution
of the CHF and reversed the dilatation of the heart ventricles
[18, 26, 133]. Speciﬁcally, closure of an AV ﬁstula, induces
both characteristic diuretic and natriuretic responses in
experimentalanimals[10,18,133]andreversaloftheclinical
signs of CHF in patients [26]. Likewise, complete reversal
of the hemodynamic abnormalities, including restoration of
peripheral vascular resistance, diastolic pressure, and mean
arterial pressure [134], in association with reduced plasma
levels of ANP were observed [135]. However, Zucker et al.
[136] demonstrated in a canine model that closure of AV
ﬁstula, although resulting in signiﬁcant regression of cardiac
dilatation, did not completely restore heart size to normal.
This most likely indicates permanent cardiac structural
changes in this experimental model.
Insummary,theACF-inducedCHFinratsisaninexpen-
sive and rapidly evolved model of cardiac hypertrophy and
remodeling. Since this model mimics high cardiac output
clinical heart failure, it may be suitable to study myocardial
alterations, mainly cardiac hypertrophy characterizing these
patients. However, since diﬀerent mechanisms underlie
pressure-as compared to volume overload-induced cardiac
remodeling,thisexperimentalmodelmaynotbeappropriate
to investigate cardiac function and hypertrophy in pressure
overload clinical settings.
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